Revascor improves survival and reduces major morbidity in high-risk ischemic heart failure patients with inflammation

Phase 3 trial results published in european journal of heart failure identify key target population for mesoblast allogeneic cell therapy phase 3 trial results published in european journal of heart failure identify key target population for mesoblast allogeneic cell therapy
MESO Ratings Summary
MESO Quant Ranking